BRAF and melanoma: The therapeutic use of targeted BRAF inhibitors have shown improved survival in adults with BRAFV600E mutated melanoma in Phase 3 clinical trials and are now part of standard clinical care, with first generation BRAF inhibitors vemurafenib and dabrafenib approved by the FDA in 2011 and 2013 respectively (16, 17).